Vor Biopharma pioneers engineered hematopoietic stem cells (eHSCs) that remove biologically redundant proteins so transplanted stem cells become invulnerable to complementary targeted therapies while tumor cells remain susceptible. Its lead candidate, VOR33, lacks CD33 and is intended to improve the therapeutic window and effectiveness of CD33-targeted therapies for acute myeloid leukemia. The company plans to use the financing to advance VOR33 into first-in-human clinical trials, deepen its portfolio, and accelerate validation of additional targets for its platform. Vor’s approach aims to change the treatment paradigm for both hematopoietic stem cell transplants and targeted therapies such as ADCs, bispecifics, and CAR-Ts. A proof-of-concept preclinical study for the lead program has been published in Proceedings of the National Academy of Sciences. Vor is based in Cambridge, Mass., and holds a broad IP base including in-licenses from Columbia University; Siddhartha Mukherjee serves as Vor’s Scientific Board Chair. Vor Biopharma's core product approach uses an engineered hematopoietic stem cell (HSC) technology platform to enable targeted immunotherapies for hematologic malignancies. The company is advancing a lead HSC-based candidate for the treatment of acute myeloid leukemia (AML) toward the clinic. Vor says its platform can expand the reach of targeted immunotherapies, enable new dosing paradigms, and improve the therapeutic window and patient safety. Proceeds from the recent financing will be used to advance the lead candidate and to further build the company’s pipeline against hematologic cancers. Vor was co-founded by PureTech Health and Siddhartha Mukherjee and collaborates with leading scientists and institutions in stem cell and immunology research. The company is publicly reported from Boston.

Total raised

$152M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2020